Summary.-Growth of transplanted rat tumours was retarded and in some cases completely suppressed when cells were injected subcutaneously in admixture with double stranded RNA (ds-RNA). This response required intimate contact between ds-RNA and tumour cells and systemic treatment with the agent failed to prevent progressive growth of a range of rat tumours. Direct cytotoxic effects of ds-RNA may contribute to tumour suppression since the compound was cytotoxic in vitro for cultured tumour cells. The involvement of host factors is suggested, however, by the in vivo tests showing variations in susceptibility to ds-RNA mediated tumour suppression similar to that previously observed with bacterial adjuvants.
ds-RNA and tumour cells and systemic treatment with the agent failed to prevent progressive growth of a range of rat tumours. Direct cytotoxic effects of ds-RNA may contribute to tumour suppression since the compound was cytotoxic in vitro for cultured tumour cells. The involvement of host factors is suggested, however, by the in vivo tests showing variations in susceptibility to ds-RNA mediated tumour suppression similar to that previously observed with bacterial adjuvants.
DOUBLE-STRANDED RNA (ds-RNA), both of natural origin (e.g. from fungal virus) or prepared synthetically (e.g. polyinosinic-polycytidylic acid, Poly I-C) has been reported to exert tumour suppressive effects in experimental animals. For example, ds-RNA treatment inhibits tumour development in mice infected neonatally with murine sarcoma virus (MSV) (De Clercq and Merigan, 1971; Sarma et al., 1969) , retards development of polyoma virus induced tumours in rats (Vandeputte et al., 1970) and retards growth of established grafts of polyoma virus induced tumour in mice (Fischer, Cooperband and Mannick, 1972) . Double-stranded RNA is a potent stimulator of interferon production (Planterose et al., 1970; Vandeputte et al., 1970) and its control of virally induced tumour has been interpreted as being mediated by increased interferon production (De Clercq and De Somer, 1971; Vandeputte et al., 1970) . However, ds-RNA also exerts tumour suppressive effects against some experimental tumours in which no viral aetiology is demonstrable. Thus, repeated interperitoneal administration of ds-RNA retards or completely prevents growth of the transplanted B 16 melanoma (Bart and Kopf, 1969;  Bart, Kopf and Silagi, 1971;  Kreider and Benjamin, 1972) and Lewis lung carcinoma (Heyes, Catherall and Harnden, 1974) in C57B1 mice, and reduces their propensity to metastasize. In addition Levy, Law and Rabson (1969) have reported that ds-RNA inhibits growth of a range of transplanted mouse tumours, all of spontaneous origin, including a reticulum cell sarcoma, a fibrosarcoma and a lymphoma. Treatment by intravenous or intraperitoneal injection was effective even if started several days after tumour challenge, and established tumours could be made to regress. Treatment also retarded growth of a transplanted rat mammary carcinoma (Kreider and Benjamin, 1972) , led to regression of established grafts of 3-methylcholanthrene (Mc) induced mouse sarcomata (Fischer et al., 1972) , and inhibited growth of the L1210 mouse leukaemia (Levy et al., 1960; Zeleznick and Bhuyan, 1969) . In a series of tests with Mc induced lymphomata and benzpyrene induced fibrosarcomata in mice, Parr, Wheeler and Alexander (1973) (1970) found that ds-RNA was ineffective in the treatment of transplanted Mc induced murine sarcomata. In addition, prolonged ds-RNA treatment increased the incidence of primary carcinogen induced thymic lymphomata (Ball and McCarter, 1971.) although it reduced the incidence of radiation induced lymphomata. Also, ds-RNA had little or no effect on the induction of tumours by SV40 virus in neonatal hamsters and did not inhibit growth of SV40 induced tumours transplanted into adult animals (Larson, Panteleakis and Hilleman, 1970) . With Friend virus induced mouse leukaemia, while treatment several days after virus infection led to a reduction in disease treatment in the early stage of infection increased its severity (Pilch and Planterose, 1971) . In addition, tumour induction by MSV in mice was retarded in very young (4-6 day old) mice by ds-RNA treatment, but enhanced in 20-day old animals (De Clercq and Merigan, 1971) . There is an indication, however, that, in addition to its systemic effects, ds-RNA may be more consistently suppressive if injected directly into the environment of tumour growth. Thus, intralesional injections of ds-RNA restricted growth of transplanted mouse tumours (Heyes et al., 1974; Parr et al., 1973) and growth of intraperitoneally injected mouse lymphoma cells was more markedly suppressed by intraperitoneal injection of ds-RNA than when the material was given by any other route (Ball and McCarter, 1971) . In addition, growth of an ascitic reticulum cell sarcoma was similarly retarded by intraperitoneal injection of ds-RNA (Levy et al., 1969) .
In view of these conflicting reports on the anti-tumour action of ds-RNA, the present studies were carried out to assess the influence of one standardized ds-RNA preparation on the growth of transplanted rat tumours. These include tumours of a number of different histological types, ranging from highly immunogenic Mc induced sarcomata to a chemically induced mammary carcinoma with no detectable immunogenic potential, and were selected to allow an assessment of host immune response in any inhibitory effects. In addition, the ability of mixed inocula of tumour cells and ds-RNA to induce tumour specific immunity, and their suitability as a vaccine for active immunotherapy, have been assessed, particularly in comparison with previous studies with BCG and tumour cell mixed inocula (Baldwin and Pimm, 1973a . Hepatoma D23, induced by oral administration of 4-dimethylaminoazobenzene, is also immunogenic, producing resistance following graft excision to challenge with up to 5 x 105 tumour cells (Baldwin and Barker, 1967; Price and Baldwin, 1974) . Mammary carcinoma AAF57 induced by repeated intraperitioneal injection of N-hydroxy-2-acetylaminofluorene lacks detectable immunogenicity, excision of subcutaneous grafts failing to elicit resistance to challenge with 1 x 103 cells, this being the minimum inoculum for growth in control rats (Baldwin and Embleton, 1974) . Epithelioma Spl arose spontaneously and is weakly immunogenic, only 5 x 104 cells being rejected by immunized animals (Baldwin, 1966; Baldwin and Embleton, 1974 Some tests were performed with ds-RNA solutions in PBS which had been dialysed for 18 h at +40C against PBS solution. (Fig. 1) .
RESULTS

Influence of systemic administration
In the second series of tests (Table II) (Fig. 2) .
The final tests (Table II) (Baldwin and Pimm, 1973a) . In these tests (Table  V) cells and ds-RNA failed to develop in all animals but there was no simultaneous rejection of the contralateral challenge inoculum of cells alone in either of 2 separate experiments. In contrast, growth of the challenge inoculum was successfully prevented in both tests in a total of 9/10 rats treated with a mixed inoculum of sarcoma Mc7 cells together with BCG.
Cytotoxicity tests
In view of the marked tumour suppressive effect of ds-RNA injected in admixture with tumour cells, further tests were carried out to assess the direct effect of ds-RNA on in vivo and in vitro growth potential of tumour cells.
In these tests (Table VI) , tumour cells were suspended in ds-RNA, at a concentration of 1 mg/ml in medium 199 and incubated at 37°C for 3 h. Cell suspensions were then either diluted directly in medium 199 (Baldwin and Pimmrl, 1971, 1973a) or mycobacterial methainol extraction residue (Hopper, Pimm and Baldwin, 1976 (Baldwin and Pimm, 1971, 1973a) . It is probable that the local tumour suppressive property of the ds-RNA preparation used in these studies is due, at least in part, to a direct effect of the material upon tumour cells. Cells incubated in ds-RNA and then washed failed to grow in vivo, although the viability of the cells at the time of injection was not affected, at least as assessed by trypan blue exclusion tests. The present tests also demonstrate that exposure of tumour cells to ds-RNA restricted their in vitro survival. Dialysis of ds-RNA against PBS did not reduce cytotoxicity, indicating that the effect was not due to osmotic imbalances or the presence of cytotoxic small molecular weight components.
It is not possible, however, to ascribe the in vivo suppression of tumour growth only to indiscriminate cytotoxicity of the material, since tumours vary markedly in their in vivo susceptibility to this treatment. For example, with the carcinogen induced mammary carcinoma AAF57, only retardation of growth was achieved with as few as 1 x 104 cells in admixture with ds-RNA, whereas with carcinogeninduced sarconiata at least 2 x 106 cells were prevented from growth. Furthermore, temporary growth of tumour cell-ds-RNA mixed inocula was sometimes observed, followed by regressions. The degree of ds-RNA mediated tumour suppression described in this paper is similar to that previously reported in comparable tests with BCG. Here, too, injection of BCG together with tumour cells restricts or prevents their development, but tumours vary markedly in their susceptibility . The mechanism of this suppression with BCG probably involves activation of host macrophages, since the effect is not altered by immunosuppression , but is abrogated by silica induced host macrophage depletion Hopper et al., 1976) . Double stranded RNA, like BCG, has been shown to be macrophage activating, rendering them cytotoxic for malignant cells (Alexander and Evans, 1971) . Further tests are therefore in progress with the experimental tumours described here to assess the influence of host macrophage depletion and immunosuppression on contact suppression of tumour growth by ds-RNA.
The mode of action of ds-RNA in the type of tumour suppression described here clearly requires further investigation but the studies indicate that treatment with the ds-RNA preparation employed (Beecham's BRL 5907) might be extended to tumours at other sites. Extensive experimental studies with BCG (Baldwin and Pimm, 1973b, c, 1974; have indicated that adjuvant contact therapy can be used to control pulmonary metastases and tumour deposits in the pleural and peritoneal cavities. These latter tests have been carried out to assess the application of the form of treatment to the clinical management of mesothelioma in man, in view of the inadequacy of conventional therapy in controlling the disease (Elmes, 1973) . Further tests have therefore been carried out with BRL 5907 to determine its influence on intraperitoneal and intrapleural tumour growths, the indication from these further studies (Pimm and Baldwin, 1976) being that this material may be as efficient as BCG in suppressing tumour growth at these sites.
